New Findings Highlight Benefits of Libre Technology for People with Type 2 Diabetes on Insulin Therapy

Abbott's Landmark Study on Diabetes Management

In a groundbreaking study, Abbott (NYSE: ABT), a leader in global healthcare, has unveiled significant findings regarding its innovative FreeStyle Libre continuous glucose monitoring (CGM) technology. The recent results, presented at the 19th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), indicate that individuals with Type 2 diabetes reliant on basal insulin can achieve improved glucose management through the use of this cutting-edge CGM system.

The Study Overview

Conducted as part of the FreeDM2 randomized controlled trial, this research involved 303 participants across 24 clinical sites in the U.K. The primary goal was to evaluate the effectiveness of the FreeStyle Libre technology compared to traditional blood glucose monitoring methods, such as fingersticks. The trial's results revealed that individuals utilizing the FreeStyle Libre system experienced a notable reduction in HbA1c levels (by 0.6%), along with spending approximately 2.5 more hours per day in a healthy glucose range, compared to those who relied solely on fingerstick methods.

Empowering Patient-Centric Management

The essence of the study emphasized the importance of participant-led self-management. By leveraging real-time glucose data provided by the FreeStyle Libre system, participants were empowered to make informed decisions related to their dietary choices, insulin dosing, and physical activity levels. This proactive approach led to substantial improvements in their glucose control, underscoring the transformative role of real-time data in managing diabetes effectively.

According to Emma Wilmot, an associate professor of diabetes and endocrinology at the University of Nottingham and co-lead investigator of the study, "This study clearly showcases the power of real-time glucose information for individuals with Type 2 diabetes who are treated with basal insulin. The ability to see their own glucose levels allowed participants to adapt their lifestyles effectively, even when already using advanced therapies like SGLT2 inhibitors and GLP-1 receptor agonists."

Insights from Accompanying Research

In tandem with the FreeDM2 trial's findings, complementary research from Italy presented at the same conference corroborated the initial study's results. This separate study tracked 88 adults with Type 2 diabetes using basal insulin and the FreeStyle Libre system in a real-world clinical context. After a three-month period, participants reported enhanced average glucose levels, more consistent glucose control, and an overall improvement in their quality of life.

Mahmood Kazemi, Abbott's Chief Medical Officer for diabetes care, highlighted the collective insights garnered from both studies, stating, "The continuous visibility into their glucose levels gives individuals the understanding needed to make precise and timely adjustments to their day-to-day habits. The similarity in findings across both studies reinforces the intrinsic value derived from continuous glucose monitoring, rather than relying on any single feature of the device."

Implications for Healthcare Accessibility

Despite the compelling evidence supporting the efficacy of CGM for individuals using basal insulin, a significant gap persists in terms of insurance coverage. Currently, many regions, including parts of Europe, primarily offer CGM reimbursement to people utilizing multiple daily insulin injections. The revelations from the FreeDM2 and Italian studies strongly advocate for broader reimbursement policies that encompass all those on basal insulin therapy.

A Revolutionary Step in Diabetes Management

Abbott's commitment to innovating diabetes management technology over the past decade has anchored its position at the forefront of healthcare solutions. The FreeStyle Libre portfolio, which has been embraced by nearly 8 million individuals across over 60 countries, demonstrates the profound impact the technology has on helping users understand their glucose patterns in real-time. With ongoing efforts to expand coverage and accessibility, Abbott envisions a future where everyone living with diabetes can benefit from essential monitoring tools.

By connecting with Abbott's resources at www.abbott.com and following the company on social media platforms, individuals can stay informed about advancements in diabetes care and technology. This landmark study is just one among many that herald a new era in diabetes management, showcasing the potential of real-time data in transforming the lives of millions struggling with this condition.